Upadacitinib for the Treatment of Recalcitrant Vulvar Lichen Sclerosus.

OBJECTIVES

Incompletely treated vulvar lichen sclerosus can lead to major complications and reduced quality of life. Limited treatment options beyond super-potent topical steroids are available for these recalcitrant cases.

METHODS

In this descriptive, retrospective case series, 3 female patients ages 36-63 presenting with recalcitrant, biopsy-proven vulvar lichen sclerosus were treated with oral upadacitinib at a dosage of 15 mg daily and monitored at 1-2 month intervals.

RESULTS

All 3 patients experienced clinical improvement in signs of lichen sclerosus and a decrease in symptom severity with minimal side effects.

CONCLUSIONS

Upadacitinib may be an effective treatment option for recalcitrant vulvar LS. More robust studies are needed to fully evaluate the efficacy and limitations of JAK inhibitors in treating lichen sclerosus.